Pathogenesis, Diagnosis, Immune Responses and Current Treatment Strategies of Covid-19
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. 2020. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Adverse Respiratory Disease 24, 91–8. https://doi.org/10.1016/j.jare.2020.03.005
Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. 2016. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends in Microbiology 24, 490–502.
Zheng J. 2020. SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. Internaional Journal Biological Sciences 16, 1678–85.
Xie M, Chen Q. 2020. Insight into 2019 novel coronavirus — an updated intrim review and lessons from SARS-CoV and MERS-CoV. International Journal of Infectious Disease. https://doi.org/10.1016/j.ijid.2020.03.071
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. 2020. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medicines and Respiration.
Chen S, Yang J, Yang W, Wang C, Bärnighausen T. 2020. COVID-19 control in China during mass population movements at New Year. Lancet 395, 764–6.
Zu ZY, Jiang M Di, Xu PP, Chen W, Ni QQ, Lu GM, Zhang LJ. 2019. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology.
Cui J, Li F, Shi ZL. 2019. Origin and evolution of pathogenic coronaviruses. Nature Reviews in Microbiology.
Hoffmann M, Kleine WH, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A. 2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 271–80.
Shirato K, Kawase M, Matsuyama S. 2018. Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry. Virology 517, 9–15. https://doi.org/10.1016/j.virol.2017.11.012
Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, Maclaren G, Brodie D. 2020. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- research that is available on the COVID-19 resource centre – including this for unrestricted research re-use. 19–21.
Shin JS, Jung E, Kim M, Baric RS, Go YY. 2020. Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro. Viruses 10.
Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, Bucci E, Piacentini M, Ippolito G, Melino G. 2020. COVID-19 infection: the perspectives on immune responses. Cell Death Difference. http://dx.doi.org/10.1038/s41418-020-0530-3
Goh KJ, Choong MC, Cheong EH, Kalimuddin S, Duu Wen S, Phua GC, Chan KS, Haja Mohideen S. 2020. Rapid Progression to Acute Respiratory Distress Syndrome: Review of Current Understanding of Critical Illness from COVID-19 Infection. Annal Academic Medical Singapore 49, 1–9.
Ahmed T, Shah RJ, Rahim SEG, Flores M, O’Linn A. 2020. Coronavirus Disease 2019 (COVID-19) Complicated by Acute Respiratory Distress Syndrome: An Internist’s Perspective. Cureus; 2019, 3–9.
Nikolich-Žugich J. 2018. The twilight of immunity: Emerging concepts in aging of the immune system review-article. Nature Immunology 19, 10–9.
Desai A, Grolleau-Julius A, Yung R. 2010. Leukocyte function in the aging immune system. Journal of Leukocyte Biology 87, 1001–9.
Chinn IK, Blackburn CC, Manley NR, Sempowski GD. 2012. Changes in Primary Lymphoid Organs With Aging $watermark-text $watermark-text $watermark-text. Seminar Immunology 24, 309–20.
Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT, Kim SJ. 2020. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). Journal of Microbiology and Biotechnology 30, 313–24.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Respiration 30, 269–71.
Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S. 2020. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect, the company’ s public news and information.
Jawhara S. 2020. Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients? International Journal Molecular Science, 21.
Watkins J. 2020. Preventing a covid-19 pandemic. BMJ 368, 1–2. http://dx.doi.org/doi:10.1136/bmj.m810
Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. 2020. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet 395, 931–4.
Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, Chan PKS, Sidwell RW. 2006. Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice. Antiviral Chemical Chemotherapy 17, 275–84.
Devaux CA, Rolain J, Colson P, Raoult D. 2020. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect , the company’ s public news and information.
Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. 2005. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology Journal 2, 1–10.
Dong L, Hu S, Gao J. 2020. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discovery and Therapy 14, 58–60.
Zhang Q, Wang Y, Qi C, Shen L, Li J. 2020. Response to “Comments on’ Zhang et al.: Clinical trial analysis of 2019-nCoV therapy registered in China’ “. Journal of Medical Virology 2019–20.